RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
June 27, 2016
Lower open expected; RegMed investors’ pre-open, take your shot and be early?
June 24, 2016
RegMed investors’ closing bell analysis: two words anticipated and stampede
June 24, 2016
Lower open expected as UK quits EU; RegMed investors’ pre-open, I am concerned with volatility
June 23, 2016
RegMed investors’ closing bell analysis: we’re up
June 15, 2016
RegMed investors’ closing bell analysis: as good as it gets?
June 15, 2016
Higher open expected; RegMed investors’ analysis, after the fall
June 14, 2016
RegMed investors’ closing bell analysis: Under a cloud, the sector follows Mesoblast down
June 13, 2016
RegMed investors’ closing bell analysis: volatility jumps
June 13, 2016
Lower open expected; RegMed investors’ analysis, no free rides in this market …
June 3, 2016
RMi’s closing bell analysis: hesitancy …
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.